Wells Fargo & Company Cuts Kestra Medical Technologies (NASDAQ:KMTS) Price Target to $27.00

Kestra Medical Technologies (NASDAQ:KMTS - Free Report) had its price objective reduced by Wells Fargo & Company from $28.00 to $27.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research firms have also weighed in on KMTS. Piper Sandler began coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They set an "overweight" rating and a $27.00 price target for the company. Wolfe Research began coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They set an "outperform" rating and a $29.00 price target for the company. Stifel Nicolaus assumed coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They set a "buy" rating and a $28.00 price target for the company. Bank of America assumed coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set a "buy" rating and a $30.00 price objective on the stock. Finally, The Goldman Sachs Group reduced their price objective on shares of Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 16th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $27.33.

Kestra Medical Technologies Stock Performance

KMTS traded down $0.56 during midday trading on Thursday, reaching $15.90. 860,676 shares of the company's stock were exchanged, compared to its average volume of 533,661. The company has a current ratio of 6.72, a quick ratio of 6.72 and a debt-to-equity ratio of 0.20. The company's 50-day moving average price is $18.89. Kestra Medical Technologies has a 1-year low of $13.25 and a 1-year high of $26.15.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Quarry LP purchased a new position in Kestra Medical Technologies during the first quarter valued at approximately $33,000. Virtu Financial LLC purchased a new position in Kestra Medical Technologies during the first quarter valued at approximately $210,000. Armistice Capital LLC purchased a new position in Kestra Medical Technologies during the first quarter valued at approximately $312,000. Zimmer Partners LP purchased a new position in Kestra Medical Technologies during the first quarter valued at approximately $374,000. Finally, Russell Investments Group Ltd. purchased a new position in Kestra Medical Technologies during the first quarter valued at approximately $457,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.